Implementation of Clinical Pharmacogenomics within a Large Health System: From Electronic Health Record Decision Support to Consultation Services

Pharmacotherapy

Volumn 36, Issue 8, 2016, Pages 940-948

  Hicks, J Kevin ^a   Stowe, David ^a   Willner, Marc A ^a   Wai, Maya ^a   Daly, Thomas ^a   Gordon, Steven M ^a   Lashner, Bret A ^a   Parikh, Sumit ^a   White, Robert ^a   Teng, Kathryn ^a   Moss, Timothy ^a   Erwin, Angelika ^a   Chalmers, Jeffrey ^a   Eng, Charis ^a   Knoer, Scott ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

clinical decision support; implementation; personalized medicine; pharmacogenomics

Indexed keywords

AZATHIOPRINE; HLA B ANTIGEN; MERCAPTOPURINE; TIOGUANINE;

ALLELE; ARTICLE; COMPUTER PROGRAM; CONSULTATION; ELECTRONIC HEALTH RECORD; GENETIC SCREENING; GENOTYPE; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH SERVICE; HUMAN; MEDICAL DECISION MAKING; MOLECULAR GENETICS; PATIENT CARE; PATIENT EDUCATION; PATIENT SAFETY; PERSONALIZED MEDICINE; PHARMACOGENOMICS; POINT OF CARE TESTING; PRACTICE GUIDELINE; WORKFLOW;

EID: 84983070459     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1786     Document Type: Article

References (33)

1. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature 2015;7573:343–50.
2. Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther 2012;4:467–75.
3. Berm EJ, Looff M, Wilffert B, et al. Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature. PLoS One 2016;1:e0146262.
4. Mason NT, Bell GC, Quilitz RE, Greene JN, McLeod HL. Budget impact analysis of CYP2C19-guided voriconazole prophylaxis in AML. J Antimicrob Chemother 2015;11:3124–6.
5. Pirmohamed M. Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. Annu Rev Genomics Hum Genet 2014;15:349–70.
6. McCarty CA, Chisholm RL, Chute CG, et al. The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics 2011;4:13 Available from http://www.biomedcentral.com/1755-8794/4/13.
7. Wilke RA, Xu H, Denny JC, et al. The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther 2011;3:379–86.
8. Bell GC, Crews KR, Wilkinson MR, et al. Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc 2014;1:e93–9.
9. Hicks JK, Crews KR, Hoffman JM, et al. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther 2012;5:563–6.
10. Pulley JM, Denny JC, Peterson JF, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther 2012;1:87–95.
11. Weitzel KW, Elsey AR, Langaee TY, et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet 2014;1:56–67.
12. Goldspiel BR, Flegel WA, DiPatrizio G, et al. Integrating pharmacogenetic information and clinical decision support into the electronic health record. J Am Med Inform Assoc 2014;3:522–8.
13. O'Donnell PH, Bush A, Spitz J, et al. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther 2012;4:446–9.
14. Peterson JF, Bowton E, Field JR, et al. Electronic health record design and implementation for pharmacogenomics: a local perspective. Genet Med 2013;10:833–41.
15. Lazaridis KN, McAllister TM, Babovic-Vuksanovic D, et al. Implementing individualized medicine into the medical practice. Am J Med Genet C Semin Med Genet 2014;1:15–23.
16. Haga SB, Allen LaPointe NM, Moaddeb J, Mills R, Patel M, Kraus WE. Pilot study: incorporation of pharmacogenetic testing in medication therapy management services. Pharmacogenomics 2014;14:1729–37.
17. Muller DJ, Kekin I, Kao AC, Brandl EJ. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. Int Rev Psychiatry 2013;5:554–71.
18. Nutescu EA, Drozda K, Bress AP, et al. Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy 2013;11:1156–64.
19. Crews KR, Cross SJ, McCormick JN, et al. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm 2011;2:143–50.
20. Mills R, Haga SB. Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists. Pharmacogenomics 2013;8:957–68.
21. Leckband SG, Kelsoe JR, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther 2013;3:324–8.
22. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011;3:387–91.
23. Martin MA, Hoffman JM, Freimuth RR, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update. Clin Pharmacol Ther 2014;5:499–500.
24. CMS. Centers for Medicare & Medicaid Services EHR Incentive Programs. Available from http://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/stage_2.html. Accessed July 27, 2015.
25. Liao KP, Cai T, Gainer V, et al. Electronic medical records for discovery research in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010;8:1120–7.
26. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011;3:464–7.
27. FDA. Table of Pharmacogenomic Biomarkers in Drug Labeling. Available from http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm. Accessed July 27, 2015.
28. Thorn CF, Klein TE, Altman RB. PharmGKB: the pharmacogenomics knowledge base. Methods Mol Biol 2013;1015:311–20. doi: 10.1007/978-1-62703-435-7_20
29. Displaying and Integrating Genetic Information Through the EHR Action Collaborative (DIGITize AC). Establishing Connectivity and Pharmacogenomic Clinical Decision Support Rules to Protect Patients Carrying HLA-B*57:01 and TPMT Variants: An Implementation Guide; 2015. Available from http://www.nationalacademies.org/hmd/~/media/Files/ActivityFiles/Research/GenomicBasedResearch/ActionCollaboratives/DIGITizEAbacavirandTPMTCDSImplementationGuide-Final1_0.pdf?la=en. Accessed July 11, 2016.
30. Rasmussen-Torvik LJ, Stallings SC, Gordon AS, et al. Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin Pharmacol Ther 2014;4:482–9.
31. Weitzel KW, Alexander M, Bernhardt BA, et al. The IGNITE network: a model for genomic medicine implementation and research. BMC Med Genomics 2016;1:1.
32. ASHP statement on the pharmacist's role in clinical pharmacogenomics. Am J Health Syst Pharm 2015;7:579–81.
33. Owusu-Obeng A, Weitzel KW, Hatton RC, et al. Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacotherapy 2014;10:1102–12.